,Gene,Gene synonym,Ensembl,Gene description,Chromosome,Position,Protein class,Evidence,Antibody,Reliability (IH),Reliability (Mouse Brain),Reliability (IF),Subcellular location,Prognostic p-value,RNA cancer category,RNA tissue category,RNA TS,RNA TS TPM,TPM max in non-specific,RNA cell line category,RNA CS,RNA CS TPM
0,A1CF,"ACF, ACF64, ACF65, APOBEC1CF, ASP",ENSG00000148584,APOBEC1 complementation factor,10,50799409-50885675,Predicted intracellular proteins,Evidence at protein level,"HPA037779, HPA044079",Enhanced,,Supported,Nucleoplasm,,Tissue enriched,Tissue enhanced,,liver: 76.0;small intestine: 29.8,duodenum: 23.5,Group enriched,18.0,CACO-2: 19.3;Hep G2: 41.7
1,ABCB1,"ABC20, CD243, CLCS, GP170, MDR1, P-gp, PGY1",ENSG00000085563,ATP binding cassette subfamily B member 1,7,87503633-87713323,"Cancer-related genes, CD markers, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"CAB001716, HPA002199",Enhanced,,Approved,Nucleoplasm<br>Focal adhesion sites<br>Cytosol,"Renal cancer:2.95e-4 (favourable), Pancreatic cancer:3.33e-4 (favourable)",Tissue enhanced,Tissue enhanced,,adrenal gland: 137.8;small intestine: 82.4,kidney: 37.3,Cell line enhanced,,CACO-2: 56.6;HEL: 34.4;SH-SY5Y: 85.9
2,ABCG2,"ABCP, BCRP, CD338, EST157481, MXR",ENSG00000118777,ATP binding cassette subfamily G member 2 (Junior blood group),4,88090264-88231322,"Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB037299, HPA054719",Enhanced,,Enhanced,Nucleus<br>Plasma membrane,,Mixed,Tissue enhanced,,small intestine: 113.8,seminal vesicle: 55.9,Cell line enhanced,,A549: 47.2;BEWO: 80.5;RPMI-8226: 32.5
3,ABHD14A-ACY1,,ENSG00000114786,ABHD14A-ACY1 readthrough,3,51974706-51989183,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA036174, HPA036175, HPA038153",Approved,,Uncertain,Vesicles,,Not detected,Tissue enhanced,,small intestine: 1.7,kidney: 0.7,Cell line enhanced,,HUVEC TERT2: 1.3;SH-SY5Y: 1.3
4,ABO,"A3GALNT, A3GALT1",ENSG00000175164,"ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase",9,133250401-133275214,Predicted membrane proteins,Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,small intestine: 17.9,colon: 7.3,Group enriched,7.0,A-431: 4.5;CAPAN-2: 18.7;HaCaT: 14.1;K-562: 18.6;RT4: 6.3
5,AC007325.2,,ENSG00000277196,,Unmapped,138082-161852,Predicted intracellular proteins,Evidence at transcript level,HPA020361,Uncertain,,,,,,Tissue enhanced,,skin: 38.5;small intestine: 37.1,duodenum: 29.0,Cell line enriched,7.0,RPTEC TERT1: 137.9
6,ACE,"ACE1, CD143, DCP1",ENSG00000159640,Angiotensin I converting enzyme,17,63477061-63498380,"Candidate cardiovascular disease genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"CAB002426, CAB002921, HPA029298, HPA069790",Enhanced,,Approved,Vesicles,,Expressed in all,Tissue enhanced,,duodenum: 178.9;small intestine: 291.6,testis: 83.7,Cell line enhanced,,ASC TERT1: 44.4;HUVEC TERT2: 28.2
7,ACY3,"ACY-3, HCBP1, MGC9740",ENSG00000132744,Aminoacylase 3,11,67642555-67650659,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA039219, HPA048187",Enhanced,,,,Endometrial cancer:4.80e-4 (favourable),Mixed,Tissue enhanced,,duodenum: 80.6;kidney: 53.3;small intestine: 78.6,"cervix, uterine: 16.1",Cell line enhanced,,CACO-2: 8.4;CAPAN-2: 13.6;Daudi: 41.2
8,ADAMDEC1,M12.219,ENSG00000134028,ADAM like decysin 1,8,24384285-24406013,"Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,,,,,,,Expressed in all,Tissue enhanced,,colon: 210.9;rectum: 339.7;small intestine: 476.3,duodenum: 189.1,Group enriched,7.0,U-266/70: 8.1;U-266/84: 1.9
9,ADGRG4,"GPR112, PGR17, RP1-299I16",ENSG00000156920,Adhesion G protein-coupled receptor G4,X,136300963-136416888,"G-protein coupled receptors, Plasma proteins, Predicted membrane proteins",Evidence at protein level,HPA035324,Uncertain,,,,,Not detected,Tissue enhanced,,duodenum: 2.5;small intestine: 1.7,fallopian tube: 0.5,Not detected,,
10,ADTRP,"AIG1L, C6orf105, dJ413H6.1",ENSG00000111863,Androgen dependent TFPI regulating protein,6,11712054-11807046,Predicted membrane proteins,Evidence at transcript level,HPA048113,Uncertain,,Uncertain,Nucleoli,Renal cancer:1.13e-5 (unfavourable),Mixed,Tissue enhanced,,small intestine: 79.4,duodenum: 61.1,Cell line enhanced,,HUVEC TERT2: 62.0;TIME: 33.0;U-138 MG: 25.7;U-266/84: 23.2
11,AGR3,"BCMP11, hAG-3, HAG3, PDIA18",ENSG00000173467,"Anterior gradient 3, protein disulphide isomerase family member",7,16859405-16881987,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA053942,Enhanced,,Supported,Endoplasmic reticulum<br>Vesicles,,Tissue enhanced,Tissue enhanced,,fallopian tube: 354.7;small intestine: 259.5,rectum: 233.8,Cell line enriched,52.0,T-47d: 316.6
12,AKR1B10,"AKR1B11, AKR1B12, ALDRLn, ARL-1, ARL1, HIS, HSI",ENSG00000198074,Aldo-keto reductase family 1 member B10,7,134527592-134541408,Predicted intracellular proteins,Evidence at protein level,"HPA020280, CAB070163, HPA073633",Enhanced,,Supported,Plasma membrane<br>Cytosol,"Renal cancer:4.80e-9 (unfavourable), Colorectal cancer:1.91e-4 (favourable)",Tissue enhanced,Tissue enhanced,,duodenum: 635.9;gallbladder: 283.3;small intestine: 387.2;stomach: 414.4,esophagus: 89.8,Group enriched,74.0,A549: 2731.1;Hep G2: 580.9
13,ANKS4B,"FLJ38819, HARP",ENSG00000175311,Ankyrin repeat and sterile alpha motif domain containing 4B,16,21233665-21253845,Predicted intracellular proteins,Evidence at protein level,HPA043523,Approved,,Approved,Nucleoplasm<br>Cytosol,,Group enriched,Tissue enhanced,,duodenum: 9.0;rectum: 7.8;small intestine: 12.9,colon: 6.8,Group enriched,10.0,CACO-2: 1.1;HDLM-2: 3.2;Hep G2: 5.5
14,ANO9,"PIG5, TMEM16J, TP53I5",ENSG00000185101,Anoctamin 9,11,417933-442011,"Predicted membrane proteins, Transporters",Evidence at protein level,"HPA039948, HPA040112",Approved,,Uncertain,Golgi apparatus,Urothelial cancer:8.81e-4 (favourable),Tissue enhanced,Tissue enhanced,,duodenum: 31.6;small intestine: 30.9,skin: 21.6,Cell line enhanced,,BEWO: 8.6;CAPAN-2: 24.1;HaCaT: 14.1;RPMI-8226: 13.6
15,AOC1,"ABP1, DAO",ENSG00000002726,"Amine oxidase, copper containing 1",7,150824627-150861504,"Enzymes, Predicted secreted proteins",Evidence at protein level,"HPA031032, HPA031033",Approved,,,,Prostate cancer:1.71e-4 (favourable),Group enriched,Tissue enhanced,,placenta: 716.9;small intestine: 247.6,duodenum: 183.2,Cell line enhanced,,CAPAN-2: 17.4;HaCaT: 5.4;THP-1: 17.8
16,APOA1,,ENSG00000118137,Apolipoprotein A1,11,116835751-116837950,"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB016778, HPA046715",Supported,,Approved,Vesicles<br>Cytosol,"Renal cancer:1.67e-8 (unfavourable), Liver cancer:5.05e-4 (favourable)",Tissue enriched,Tissue enhanced,,liver: 8458.6;small intestine: 4128.6,duodenum: 1609.4,Cell line enriched,15.0,Hep G2: 1951.8
17,AQP11,,ENSG00000178301,Aquaporin 11,11,77589391-77610355,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA042879,Approved,,Approved,Nucleoplasm<br>Vesicles,Ovarian cancer:9.89e-4 (favourable),Mixed,Tissue enhanced,,duodenum: 24.1;small intestine: 23.1,adrenal gland: 10.0,Cell line enhanced,,Hep G2: 7.7
18,B3GNT8,"B3GALT7, beta3Gn-T8, BGALT15",ENSG00000177191,"UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 8",19,41425359-41428730,Predicted secreted proteins,Evidence at protein level,HPA043669,Enhanced,,,,"Pancreatic cancer:9.31e-6 (favourable), Endometrial cancer:4.11e-4 (unfavourable)",Mixed,Tissue enhanced,,duodenum: 15.5;small intestine: 16.8,esophagus: 10.7,Cell line enhanced,,HMC-1: 5.7;HUVEC TERT2: 2.9;U-937: 4.3
19,BAIAP2L2,"FLJ22582, pinkbar",ENSG00000128298,BAI1 associated protein 2 like 2,22,38084889-38110670,Predicted intracellular proteins,Evidence at protein level,HPA003043,Approved,,,,,Expressed in all,Tissue enhanced,,duodenum: 107.2;small intestine: 97.5,gallbladder: 27.4,Cell line enhanced,,RPTEC TERT1: 22.3;SK-MEL-30: 29.5;WM-115: 29.0
20,BCL2L15,"Bfk, C1orf178, FLJ22588",ENSG00000188761,BCL2 like 15,1,113878168-113887547,Predicted intracellular proteins,Evidence at protein level,"HPA029732, HPA029733",Enhanced,,,,Endometrial cancer:5.63e-4 (favourable),Tissue enhanced,Tissue enhanced,,colon: 47.4;duodenum: 66.5;rectum: 52.2;small intestine: 64.3,stomach: 24.0,Cell line enhanced,,CAPAN-2: 22.4;EFO-21: 8.1;RPTEC TERT1: 5.6
21,BCO1,"BCDO, BCDO1, BCMO, BCMO1, FLJ10730",ENSG00000135697,Beta-carotene oxygenase 1,16,81238448-81291142,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA043811,,,Uncertain,Actin filaments<br>Microtubule organizing center,,Mixed,Tissue enhanced,,duodenum: 8.7;small intestine: 14.8,kidney: 3.3,Cell line enhanced,,A549: 9.9;EFO-21: 7.6;HAP1: 3.2;NTERA-2: 4.4;RPTEC TERT1: 6.2
22,BRINP3,"DBCCR1L, DBCCR1L1, FAM5C",ENSG00000162670,BMP/retinoic acid inducible neural specific 3,1,190097662-190478404,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA054693,Uncertain,,,,,Group enriched,Tissue enhanced,,cerebral cortex: 44.5;small intestine: 19.6,prostate: 10.9,Cell line enriched,6.0,SCLC-21H: 17.0
23,C1orf106,FLJ10901,ENSG00000163362,Chromosome 1 open reading frame 106,1,200891048-200915735,Predicted intracellular proteins,Evidence at transcript level,"HPA027499, HPA027511",Uncertain,,,,Endometrial cancer:1.78e-5 (unfavourable),Expressed in all,Tissue enhanced,,small intestine: 69.7,duodenum: 54.3,Cell line enhanced,,BEWO: 60.4;HaCaT: 66.8
24,C1QTNF12,"ADIPOLIN, C1QDC2, CTRP12, FAM132A, MGC105127",ENSG00000184163,C1q and tumor necrosis factor related protein 12,1,1242446-1246722,Predicted secreted proteins,Evidence at protein level,HPA024107,Approved,,Approved,Vesicles,,Mixed,Tissue enhanced,,duodenum: 6.9;small intestine: 7.3,colon: 2.1,Group enriched,5.0,EFO-21: 3.9;U-2 OS: 4.3
25,C6orf222,DKFZp779B1540,ENSG00000189325,Chromosome 6 open reading frame 222,6,36315757-36336885,Predicted intracellular proteins,Evidence at protein level,"HPA038407, HPA058189",Uncertain,,,,,Group enriched,Tissue enhanced,,duodenum: 24.7;small intestine: 26.4,rectum: 6.2,Not detected,,
26,CALML4,"MGC4809, NY-BR-20",ENSG00000129007,Calmodulin like 4,15,68190705-68206110,"Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,HPA051109,Enhanced,,Approved,Nucleoplasm<br>Golgi apparatus<br>Cytosol,,Mixed,Tissue enhanced,,duodenum: 79.8;small intestine: 74.4,colon: 58.5,Mixed,,
27,CAPN13,FLJ23523,ENSG00000162949,Calpain 13,2,30722771-30820542,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA029496, HPA029497, HPA030034",Uncertain,,Approved,Nucleoplasm,,Mixed,Tissue enhanced,,rectum: 26.8;small intestine: 32.4;stomach: 26.5,duodenum: 20.8,Cell line enhanced,,RT4: 7.4;SK-BR-3: 16.4;T-47d: 2.8
28,CBLC,"CBL-3, CBL-SL, RNF57",ENSG00000142273,Cbl proto-oncogene C,19,44777869-44800634,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB008087, HPA035266",Approved,,Approved,Nucleoplasm,Renal cancer:3.11e-6 (favourable),Mixed,Tissue enhanced,,duodenum: 52.5;skin: 41.9;small intestine: 44.0,colon: 21.4,Cell line enhanced,,A-431: 38.2;BEWO: 28.0;CACO-2: 23.9;CAPAN-2: 51.1;HaCaT: 37.6;HBEC3-KT: 25.9;RT4: 29.6;SK-BR-3: 24.0
29,CCL11,"eotaxin, MGC22554, SCYA11",ENSG00000172156,C-C motif chemokine ligand 11,17,34285668-34288334,"Cancer-related genes, Predicted secreted proteins",Evidence at protein level,,,,,,"Head and neck cancer:1.99e-4 (favourable), Colorectal cancer:8.70e-4 (favourable)",Mixed,Tissue enhanced,,appendix: 39.3;small intestine: 37.3,duodenum: 30.8,Cell line enriched,18.0,BJ hTERT+: 7.2
30,CCL15,"HCC-2, HMRP-2B, Lkn-1, MIP-1d, MIP-5, NCC-3, SCYA15, SCYL3",ENSG00000275718,C-C motif chemokine ligand 15,17,35996440-36002038,"Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA058608,,,Approved,Golgi apparatus<br>Vesicles,Urothelial cancer:3.02e-4 (favourable),Tissue enhanced,Tissue enhanced,,duodenum: 21.5;rectum: 30.6;small intestine: 26.6,colon: 18.9,Cell line enriched,12.0,Hep G2: 22.7
31,CCL24,"Ckb-6, eotaxin-2, MPIF-2, MPIF2, SCYA24",ENSG00000106178,C-C motif chemokine ligand 24,7,75811665-75823356,Predicted secreted proteins,Evidence at protein level,,,,,,Colorectal cancer:5.41e-4 (favourable),Tissue enhanced,Tissue enhanced,,rectum: 111.7;small intestine: 96.2,urinary bladder: 51.4,Cell line enhanced,,CAPAN-2: 4.8;RH-30: 2.0;U-2 OS: 5.9
32,CHN2,"ARHGAP3, RhoGAP3",ENSG00000106069,Chimerin 2,7,29122274-29514328,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA018989,Approved,,Approved,Nucleus,,Mixed,Tissue enhanced,,duodenum: 74.8;small intestine: 68.4,cerebral cortex: 31.7,Cell line enhanced,,HEL: 34.5;HMC-1: 60.7
33,CHRM4,,ENSG00000180720,Cholinergic receptor muscarinic 4,11,46385098-46386608,"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,"CAB022444, HPA072083",Uncertain,,Uncertain,Nucleus<br>Golgi apparatus,,Mixed,Tissue enhanced,,cerebral cortex: 8.1;small intestine: 7.8;spleen: 21.4,testis: 6.9,Cell line enhanced,,RH-30: 3.3;SCLC-21H: 11.7;U-2 OS: 3.0
34,CHRNA7,,ENSG00000175344,Cholinergic receptor nicotinic alpha 7 subunit,15,31923438-32173018,"FDA approved drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA029422, CAB033624",Enhanced,,,,,Mixed,Tissue enhanced,,adrenal gland: 9.4;small intestine: 10.4,stomach: 6.2,Cell line enhanced,,AN3-CA: 5.8;RT4: 9.8;SH-SY5Y: 7.1;SK-BR-3: 10.0;U-2 OS: 11.2
35,CHST6,MCDC1,ENSG00000183196,Carbohydrate sulfotransferase 6,16,75472052-75495384,"Disease related genes, Predicted secreted proteins",Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,"cervix, uterine: 16.3;duodenum: 10.6;small intestine: 10.9",cerebral cortex: 7.9,Cell line enhanced,,AN3-CA: 10.8;CAPAN-2: 11.4;NTERA-2: 6.2;U-2 OS: 8.0;WM-115: 6.7
36,CLDN3,"C7orf1, CPE-R2, CPETR2, HRVP1, RVP1",ENSG00000165215,Claudin 3,7,73768997-73770270,"Cancer-related genes, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,"CAB002702, HPA014361",Supported,,Supported,Cell Junctions,Renal cancer:3.39e-5 (favourable),Mixed,Tissue enhanced,,colon: 87.7;small intestine: 119.5,duodenum: 55.0,Cell line enhanced,,MCF7: 175.3;PC-3: 44.1;SCLC-21H: 68.2;T-47d: 98.9
37,CYP2J2,,ENSG00000134716,Cytochrome P450 family 2 subfamily J member 2,1,59893308-59926790,"Enzymes, Predicted secreted proteins",Evidence at protein level,,,,,,Renal cancer:5.54e-7 (unfavourable),Mixed,Tissue enhanced,,liver: 74.4;small intestine: 92.3,heart muscle: 57.5,Cell line enhanced,,RT4: 48.3;SK-BR-3: 12.0
38,CYP2S1,,ENSG00000167600,Cytochrome P450 family 2 subfamily S member 1,19,41193049-41207539,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA049227, HPA069248",Approved,,Approved,Endoplasmic reticulum,Renal cancer:1.60e-6 (unfavourable),Expressed in all,Tissue enhanced,,duodenum: 96.7;small intestine: 68.6;stomach: 111.7,colon: 25.9,Cell line enhanced,,A549: 83.4;CACO-2: 39.6;HaCaT: 43.5;NTERA-2: 68.5
39,CYP3A5,"CP35, P450PCN3, PCN3",ENSG00000106258,Cytochrome P450 family 3 subfamily A member 5,7,99648194-99679998,"Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA072245,,,Uncertain,Cytosol,Liver cancer:3.72e-5 (favourable),Tissue enhanced,Tissue enhanced,,duodenum: 114.8;liver: 93.2;small intestine: 187.6,stomach: 77.7,Cell line enhanced,,A549: 2.5;CACO-2: 7.9;CAPAN-2: 5.7;Hep G2: 5.0
40,CYP4F11,,ENSG00000171903,Cytochrome P450 family 4 subfamily F member 11,19,15912367-15934867,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA017265, CAB033648, HPA058960",Enhanced,,,,"Breast cancer:4.05e-4 (favourable), Pancreatic cancer:9.28e-4 (unfavourable)",Mixed,Tissue enhanced,,gallbladder: 29.5;liver: 32.7;small intestine: 26.3,epididymis: 20.0,Cell line enhanced,,A-431: 11.4;CAPAN-2: 44.2;EFO-21: 17.4;Hep G2: 17.0;RT4: 12.1
41,CYP4F12,,ENSG00000186204,Cytochrome P450 family 4 subfamily F member 12,19,15672757-15697174,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA058960,Approved,,,,"Cervical cancer:1.21e-4 (favourable), Urothelial cancer:2.33e-4 (favourable)",Group enriched,Tissue enhanced,,duodenum: 36.2;small intestine: 42.3,skin: 22.3,Cell line enhanced,,CAPAN-2: 14.8;HaCaT: 26.3;Karpas-707: 14.2;SiHa: 6.0
42,DAB1,,ENSG00000173406,"DAB1, reelin adaptor protein",1,56994778-58546734,Predicted intracellular proteins,Evidence at protein level,"CAB032329, HPA052033, HPA067495",Enhanced,,Supported,Vesicles,,Mixed,Tissue enhanced,,duodenum: 15.9;seminal vesicle: 13.8;small intestine: 24.8,prostate: 6.4,Cell line enhanced,,fHDF/TERT166: 41.8;HeLa: 12.9;NTERA-2: 23.4;RT4: 25.5;WM-115: 26.3
43,DDC,AADC,ENSG00000132437,Dopa decarboxylase,7,50458436-50565457,"Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins",Evidence at protein level,HPA017742,Enhanced,,Approved,Actin filaments,,Mixed,Tissue enhanced,,duodenum: 155.2;kidney: 320.9;small intestine: 180.5,adrenal gland: 63.8,Group enriched,9.0,CACO-2: 44.3;Hep G2: 32.3;SCLC-21H: 154.0;SH-SY5Y: 144.1
44,DEGS2,"C14orf66, DES2, FADS8",ENSG00000168350,"Delta 4-desaturase, sphingolipid 2",14,100143957-100160163,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA046644,,,Approved,Nucleus<br>Nucleoli,"Renal cancer:7.94e-7 (favourable), Urothelial cancer:1.66e-4 (favourable)",Mixed,Tissue enhanced,,skin: 31.4;small intestine: 38.7,duodenum: 24.8,Cell line enriched,16.0,T-47d: 98.2
45,DGAT1,"ARGP1, DGAT",ENSG00000185000,Diacylglycerol O-acyltransferase 1,8,144314584-144326910,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,CAB032853,Enhanced,,Approved,Nucleoli<br>Endoplasmic reticulum,,Expressed in all,Tissue enhanced,,duodenum: 71.3;small intestine: 75.1,adipose tissue: 20.0,Cell line enhanced,,PC-3: 35.6
46,DMBT1,"GP340, muclin, SALSA",ENSG00000187908,Deleted in malignant brain tumors 1,10,122560665-122643736,"Disease related genes, Predicted secreted proteins",Evidence at protein level,HPA040778,Enhanced,,Approved,Microtubule organizing center,Endometrial cancer:1.43e-4 (favourable),Group enriched,Tissue enhanced,,duodenum: 816.7;small intestine: 277.6,salivary gland: 136.1,Cell line enhanced,,hTERT-HME1: 3.5;LHCN-M2: 7.8;RH-30: 20.9
47,DNASE1,DNL1,ENSG00000213918,Deoxyribonuclease 1,16,3611728-3680143,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA010703,Enhanced,,Supported,Vesicles,Urothelial cancer:1.14e-4 (favourable),Expressed in all,Tissue enhanced,,small intestine: 37.8,duodenum: 29.9,Mixed,,
48,DPEP1,,ENSG00000015413,Dipeptidase 1 (renal),16,89613308-89638456,"Enzymes, FDA approved drug targets, Predicted secreted proteins",Evidence at protein level,"HPA009426, HPA012783",Enhanced,,Approved,Nucleus<br>Cell Junctions,Renal cancer:6.84e-4 (favourable),Tissue enriched,Tissue enhanced,,kidney: 262.6;small intestine: 418.9,pancreas: 92.8,Cell line enhanced,,Hep G2: 22.4;HHSteC: 11.8;U-937: 36.5
49,DQX1,FLJ23757,ENSG00000144045,DEAQ-box RNA dependent ATPase 1,2,74518131-74526336,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA039158,Enhanced,,Approved,Plasma membrane<br>Cytosol,,Mixed,Tissue enhanced,,duodenum: 14.4;small intestine: 13.5,colon: 5.5,Cell line enhanced,,HBEC3-KT: 4.2;Hep G2: 11.5;hTCEpi: 4.3
50,EDN2,ET2,ENSG00000127129,Endothelin 2,1,41478775-41484673,Predicted secreted proteins,Evidence at protein level,HPA028459,Uncertain,,Approved,Cytosol,"Endometrial cancer:2.85e-4 (unfavourable), Pancreatic cancer:5.81e-4 (unfavourable)",Tissue enhanced,Tissue enhanced,,esophagus: 10.6;small intestine: 18.1,epididymis: 5.5,Cell line enhanced,,CAPAN-2: 12.3;EFO-21: 32.7;SCLC-21H: 19.7;SK-BR-3: 31.2;U-2 OS: 16.7
51,EDN3,ET3,ENSG00000124205,Endothelin 3,20,59300427-59325992,"Disease related genes, Predicted secreted proteins",Evidence at protein level,HPA036618,,Supported,,,Glioma:2.38e-4 (favourable),Mixed,Tissue enhanced,,small intestine: 39.3,duodenum: 38.3,Not detected,,
52,ENPP3,"B10, CD203c, gp130RB13-6, PD-IBETA, PDNP3",ENSG00000154269,Ectonucleotide pyrophosphatase/phosphodiesterase 3,6,131628442-131747418,"CD markers, Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA043772,Enhanced,,,,Renal cancer:1.96e-4 (unfavourable),Tissue enriched,Tissue enhanced,,"cervix, uterine: 45.4;small intestine: 49.9",seminal vesicle: 22.0,Group enriched,15.0,HEL: 3.9;Hep G2: 9.9;HMC-1: 5.4
53,ENTPD8,"NTPDase-8, UNQ2492",ENSG00000188833,Ectonucleoside triphosphate diphosphohydrolase 8,9,137434364-137441816,"Enzymes, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA021509,Enhanced,,Approved,Nucleoplasm<br>Vesicles<br>Cytosol,Stomach cancer:7.17e-4 (favourable),Mixed,Tissue enhanced,,colon: 21.7;duodenum: 28.7;small intestine: 31.6,rectum: 12.5,Cell line enhanced,,CAPAN-2: 4.8;RPMI-8226: 3.7;T-47d: 2.7
54,EPCAM,"17-1A, 323/A3, CD326, CO-17A, EGP-2, EGP34, EGP40, Ep-CAM, ESA, GA733-2, HEA125, KS1/4, KSA, Ly74, M4S1, MH99, MIC18, MK-1, MOC31, TACST-1, TACSTD1, TROP1",ENSG00000119888,Epithelial cell adhesion molecule,2,47345158-47387601,"Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"CAB003809, HPA026761, CAB030012, CAB055098, HPA067463",Enhanced,,Supported,Plasma membrane,"Renal cancer:1.04e-6 (favourable), Ovarian cancer:3.30e-4 (favourable)",Mixed,Tissue enhanced,,rectum: 680.5;small intestine: 714.7,colon: 659.9,Cell line enhanced,,A-431: 382.2;CACO-2: 461.4;CAPAN-2: 680.1;SCLC-21H: 345.3
55,FAM3B,"2-21, C21orf11, C21orf76, D21M16SJHU19e, ORF9, PANDER, PRED44",ENSG00000183844,Family with sequence similarity 3 member B,21,41304212-41357431,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA015885, HPA029777",Approved,,Approved,Vesicles,,Tissue enhanced,Tissue enhanced,,duodenum: 162.1;small intestine: 166.8,stomach: 124.0,Cell line enhanced,,CACO-2: 16.2;CAPAN-2: 10.8;Hep G2: 22.1;RPMI-8226: 62.5
56,FAM83E,FLJ20200,ENSG00000105523,Family with sequence similarity 83 member E,19,48600810-48614854,Predicted intracellular proteins,Evidence at protein level,HPA049305,Uncertain,,,,,Mixed,Tissue enhanced,,duodenum: 30.8;small intestine: 35.3;stomach: 40.7,colon: 22.5,Cell line enhanced,,CAPAN-2: 2.9
57,FLJ22763,,ENSG00000241224,Uncharacterized LOC401081,3,109118252-109150514,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at transcript level,,,,,,,Tissue enhanced,Tissue enhanced,,duodenum: 97.6;small intestine: 94.5,kidney: 19.5,Cell line enhanced,,CACO-2: 1.0
58,FLVCR1,"AXPC1, FLVCR, MFSD7B, PCA",ENSG00000162769,Feline leukemia virus subgroup C cellular receptor 1,1,212858255-212899363,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,HPA046646,Approved,,Approved,Cell Junctions,"Renal cancer:1.06e-5 (unfavourable), Liver cancer:2.52e-5 (unfavourable), Pancreatic cancer:3.50e-4 (favourable)",Expressed in all,Tissue enhanced,,small intestine: 21.4,duodenum: 9.8,Expressed in all,,
59,FUT3,"CD174, LE",ENSG00000171124,Fucosyltransferase 3 (Lewis blood group),19,5842888-5851474,"Blood group antigen proteins, Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA046966,Supported,,,,"Renal cancer:8.22e-7 (favourable), Breast cancer:6.86e-4 (unfavourable)",Tissue enhanced,Tissue enhanced,,colon: 68.0;esophagus: 83.0;small intestine: 63.1,rectum: 49.4,Group enriched,5.0,A-431: 40.5;RH-30: 14.4
60,GAL3ST1,CST,ENSG00000128242,Galactose-3-O-sulfotransferase 1,22,30554635-30574587,"Enzymes, Predicted secreted proteins",Evidence at protein level,HPA001220,Approved,,Approved,Vesicles,Renal cancer:1.79e-4 (unfavourable),Tissue enriched,Tissue enhanced,,cerebral cortex: 18.0;duodenum: 23.2;small intestine: 27.0,kidney: 10.1,Cell line enhanced,,A549: 25.1;EFO-21: 13.7
61,GATA5,"bB379O24.1, GATAS",ENSG00000130700,GATA binding protein 5,20,62463497-62475970,"Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA067583,,,Approved,Nucleoplasm<br>Cytosol,,Tissue enhanced,Tissue enhanced,,duodenum: 11.4;small intestine: 11.0;testis: 8.7,stomach: 7.5,Cell line enhanced,,HEL: 2.6;K-562: 4.2;SiHa: 2.1;T-47d: 4.4
62,GCG,"GLP1, GLP2, GRPP",ENSG00000115263,Glucagon,2,162142873-162152404,Predicted secreted proteins,Evidence at protein level,"CAB000040, HPA036760, HPA036761",Enhanced,,Supported,Endoplasmic reticulum<br>Vesicles,,Tissue enriched,Tissue enhanced,,pancreas: 346.3;rectum: 137.2;small intestine: 123.9,colon: 69.4,Group enriched,7.0,EFO-21: 100.6;U-2 OS: 158.1
63,GCNT3,"C2/4GnT, C2GnT-M, C2GnT2",ENSG00000140297,"Glucosaminyl (N-acetyl) transferase 3, mucin type",15,59594875-59640239,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA011154,Enhanced,,Approved,Golgi apparatus<br>Vesicles,"Liver cancer:6.49e-5 (unfavourable), Endometrial cancer:1.78e-4 (favourable)",Tissue enhanced,Tissue enhanced,,colon: 142.2;gallbladder: 118.0;rectum: 134.6;small intestine: 138.4,duodenum: 97.7,Cell line enriched,6.0,A549: 133.3
64,GDA,,ENSG00000119125,Guanine deaminase,9,72114595-72257193,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA019352, HPA024099, HPA030387",Enhanced,,Approved,Nucleus,Renal cancer:2.66e-5 (favourable),Mixed,Tissue enhanced,,cerebral cortex: 102.2;duodenum: 95.2;small intestine: 104.1,kidney: 43.6,Cell line enhanced,,A-431: 31.0;EFO-21: 125.3;HeLa: 32.0;hTCEpi: 45.2
65,GIMD1,,ENSG00000250298,GIMAP family P-loop NTPase domain containing 1,4,106357485-106368825,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Not detected,Tissue enhanced,,duodenum: 28.6;small intestine: 18.0,gallbladder: 4.9,Not detected,,
66,GLOD5,,ENSG00000171433,Glyoxalase domain containing 5,X,48761750-48773648,Predicted intracellular proteins,Evidence at protein level,HPA010667,Uncertain,,Uncertain,Mitochondria,,Mixed,Tissue enhanced,,duodenum: 10.8;kidney: 11.0;small intestine: 10.7,epididymis: 6.8,Cell line enhanced,,MCF7: 1.6
67,GNAT3,"GDCA, gustducin",ENSG00000214415,G protein subunit alpha transducin 3,7,80458671-80512020,Predicted intracellular proteins,Evidence at protein level,,,,,,,Group enriched,Tissue enhanced,,duodenum: 1.9;small intestine: 1.4,testis: 0.5,Cell line enriched,8.0,SCLC-21H: 3.9
68,GNG13,"G(gamma)13, h2-35",ENSG00000127588,G protein subunit gamma 13,16,798041-800733,"Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,HPA046272,Approved,,,,,Mixed,Tissue enhanced,,cerebral cortex: 2.5;duodenum: 1.4;small intestine: 1.4,colon: 0.7,Cell line enhanced,,CACO-2: 8.6;HEK93: 8.3;MCF7: 10.0
69,GOLT1A,"CGI-141, FLJ42654, GOT1, MGC62027, YMR292W",ENSG00000174567,Golgi transport 1A,1,204198160-204214092,Predicted membrane proteins,Evidence at protein level,,,,,,"Renal cancer:6.35e-5 (unfavourable), Urothelial cancer:1.51e-4 (favourable), Glioma:5.49e-4 (unfavourable)",Tissue enriched,Tissue enhanced,,duodenum: 40.3;liver: 79.1;small intestine: 42.3,parathyroid gland: 28.1,Cell line enhanced,,CACO-2: 12.3;CAPAN-2: 14.9;Hep G2: 14.6;MCF7: 27.7;RT4: 18.6;SK-BR-3: 17.2
70,GPR35,,ENSG00000178623,G protein-coupled receptor 35,2,240605431-240631259,"G-protein coupled receptors, Predicted membrane proteins, Transporters",Evidence at transcript level,,,,,,"Renal cancer:2.59e-5 (unfavourable), Lung cancer:5.86e-4 (unfavourable)",Tissue enhanced,Tissue enhanced,,duodenum: 41.4;small intestine: 42.3,colon: 18.4,Cell line enhanced,,CACO-2: 17.1;CAPAN-2: 45.0;HDLM-2: 16.3;Hep G2: 22.7;HMC-1: 27.8
71,GSDMB,"GSDML, PRO2521",ENSG00000073605,Gasdermin B,17,39904595-39919854,"Predicted intracellular proteins, Transporters",Evidence at protein level,"CAB013681, HPA023925, HPA052407",Enhanced,,,,"Renal cancer:5.13e-11 (unfavourable), Urothelial cancer:5.91e-9 (favourable), Cervical cancer:3.41e-5 (favourable)",Expressed in all,Tissue enhanced,,duodenum: 67.0;small intestine: 85.1,rectum: 62.6,Cell line enriched,7.0,SK-BR-3: 342.4
72,GUCA2B,,ENSG00000044012,Guanylate cyclase activator 2B,1,42153421-42155824,"Plasma proteins, Predicted secreted proteins",Evidence at protein level,,,,,,,Tissue enhanced,Tissue enhanced,,colon: 87.6;small intestine: 148.3,duodenum: 37.5,Group enriched,6.0,A549: 1.3;CACO-2: 3.2
73,HEPACAM2,FLJ38683,ENSG00000188175,HEPACAM family member 2,7,93188586-93226524,Predicted membrane proteins,Evidence at protein level,,,,,,Colorectal cancer:9.73e-5 (favourable),Mixed,Tissue enhanced,,colon: 64.3;rectum: 103.1;small intestine: 53.6,duodenum: 30.2,Cell line enriched,47.0,SCLC-21H: 202.2
74,HKDC1,"FLJ22761, FLJ37767",ENSG00000156510,Hexokinase domain containing 1,10,69220303-69267559,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA011956, HPA064198, HPA064230",Approved,,Enhanced,Mitochondria,,Mixed,Tissue enhanced,,duodenum: 53.1;small intestine: 52.3,thyroid gland: 15.2,Group enriched,6.0,A549: 35.7;CACO-2: 46.7;CAPAN-2: 96.8;EFO-21: 31.5;Hep G2: 22.5;RPTEC TERT1: 61.4
75,HNF1A,"HNF1, LFB1, MODY3, TCF1",ENSG00000135100,HNF1 homeobox A,12,120978543-121002512,"Cancer-related genes, Predicted intracellular proteins",Evidence at protein level,"CAB010430, HPA035231",Enhanced,,Supported,Nucleoplasm,,Mixed,Tissue enhanced,,duodenum: 15.5;kidney: 10.6;small intestine: 15.7,liver: 6.3,Group enriched,7.0,A549: 8.0;CACO-2: 24.3;Hep G2: 22.1
76,HRASLS2,FLJ20556,ENSG00000133328,HRAS like suppressor 2,11,63552770-63563383,Predicted membrane proteins,Evidence at protein level,HPA058997,Approved,,Approved,Mitochondria,"Pancreatic cancer:5.27e-5 (unfavourable), Cervical cancer:6.87e-4 (favourable)",Mixed,Tissue enhanced,,duodenum: 67.6;small intestine: 46.5,rectum: 14.4,Cell line enriched,7.0,U-266/70: 97.6
77,HTR4,5-HT4,ENSG00000164270,5-hydroxytryptamine receptor 4,5,148451032-148677235,"FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA040591,Approved,,,,,Not detected,Tissue enhanced,,duodenum: 4.8;small intestine: 10.0,rectum: 3.1,Not detected,,
78,ITLN1,"FLJ20022, hIntL, HL-1, ITLN, LFR",ENSG00000179914,Intelectin 1,1,160876539-160885170,"Plasma proteins, Predicted secreted proteins",Evidence at protein level,"CAB012652, HPA063275, HPA067326",Enhanced,,,,,Tissue enhanced,Tissue enhanced,,colon: 447.7;rectum: 1428.1;small intestine: 468.9,duodenum: 276.3,Cell line enhanced,,HEL: 2.3;HL-60: 1.5;U-937: 5.7
79,ITPKA,"IP3-3KA, IP3KA",ENSG00000137825,Inositol-trisphosphate 3-kinase A,15,41493393-41503551,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA040454,Enhanced,Approved,Approved,Vesicles,"Renal cancer:3.76e-9 (unfavourable), Glioma:5.08e-4 (unfavourable)",Mixed,Tissue enhanced,,cerebral cortex: 25.7;duodenum: 17.7;small intestine: 19.8,stomach: 8.9,Cell line enhanced,,Hep G2: 22.6
80,KCNH6,"erg2, HERG2, Kv11.2",ENSG00000173826,Potassium voltage-gated channel subfamily H member 6,17,63523334-63548977,"Predicted membrane proteins, Voltage-gated ion channels",Evidence at protein level,,,,,,,Tissue enhanced,Tissue enhanced,,kidney: 6.1;prostate: 5.4;small intestine: 5.5,duodenum: 2.2,Group enriched,6.0,SCLC-21H: 4.0;SH-SY5Y: 1.4
81,KCNK5,"K2p5.1, TASK-2",ENSG00000164626,Potassium two pore domain channel subfamily K member 5,6,39188973-39229450,"Predicted membrane proteins, Transporters, Voltage-gated ion channels",Evidence at protein level,HPA059148,Uncertain,,Approved,Nucleus,"Renal cancer:4.98e-7 (favourable), Cervical cancer:3.29e-4 (favourable), Urothelial cancer:4.45e-4 (favourable), Pancreatic cancer:5.85e-4 (unfavourable)",Mixed,Tissue enhanced,,small intestine: 39.3,gallbladder: 29.5,Cell line enhanced,,CACO-2: 28.9;HEL: 32.6;HMC-1: 28.2;K-562: 30.8
82,KRT20,"CK20, K20, MGC35423",ENSG00000171431,Keratin 20,17,40875941-40885227,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB000032, HPA024309, HPA024684, HPA027236",Enhanced,,Supported,Cytosol,"Renal cancer:1.32e-4 (unfavourable), Liver cancer:7.05e-4 (unfavourable)",Group enriched,Tissue enhanced,,colon: 356.1;duodenum: 252.4;rectum: 295.3;small intestine: 499.6,stomach: 82.3,Cell line enhanced,,BEWO: 1.0;RT4: 2.3
83,KRT8,"CARD2, CK8, CYK8, K2C8, K8, KO",ENSG00000170421,Keratin 8,12,52897187-52949954,"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB000131, CAB001696, HPA049866",Enhanced,,Supported,Intermediate filaments,Pancreatic cancer:1.51e-4 (unfavourable),Mixed,Tissue enhanced,,small intestine: 1475.5,duodenum: 1118.4,Cell line enhanced,,A549: 5518.3;BEWO: 3855.6;CACO-2: 6334.4;CAPAN-2: 4191.3;MCF7: 7987.2;SK-BR-3: 3839.1;T-47d: 4059.8
84,LBX2,,ENSG00000179528,Ladybird homeobox 2,2,74497517-74503316,"Predicted intracellular proteins, Transcription factors",Evidence at transcript level,HPA044257,Uncertain,,Approved,Nucleus<br>Midbody,,Mixed,Tissue enhanced,,duodenum: 5.3;small intestine: 5.3,stomach: 3.0,Cell line enhanced,,Hep G2: 14.9
85,LCN15,"PRO6093, UNQ2541",ENSG00000177984,Lipocalin 15,9,136759634-136766255,Predicted secreted proteins,Evidence at protein level,HPA060584,Enhanced,,,,,Tissue enriched,Tissue enhanced,,duodenum: 12.1;seminal vesicle: 5.0;small intestine: 4.0,colon: 2.8,Group enriched,14.0,Hep G2: 11.9;SCLC-21H: 3.0
86,LGALS2,HL14,ENSG00000100079,Galectin 2,22,37570246-37582616,Predicted intracellular proteins,Evidence at protein level,"HPA003536, CAB025198",Enhanced,,Approved,Nucleoplasm<br>Mitochondria,,Expressed in all,Tissue enhanced,,gallbladder: 537.1;small intestine: 225.0,kidney: 155.6,Group enriched,13.0,CACO-2: 92.0;Hep G2: 42.9
87,LGALS4,GAL4,ENSG00000171747,Galectin 4,19,38801671-38813364,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB025653, HPA031184, HPA031185, HPA031186",Enhanced,,Uncertain,Plasma membrane,"Renal cancer:2.28e-4 (unfavourable), Urothelial cancer:3.21e-4 (favourable)",Group enriched,Tissue enhanced,,colon: 736.0;duodenum: 526.9;rectum: 640.3;small intestine: 493.5,gallbladder: 138.8,Cell line enhanced,,CACO-2: 1.0;RT4: 2.2;SH-SY5Y: 1.0
88,LRRC66,,ENSG00000188993,Leucine rich repeat containing 66,4,51993702-52017620,Predicted membrane proteins,Evidence at transcript level,"HPA014549, HPA027839",Uncertain,,,,,Mixed,Tissue enhanced,,duodenum: 22.5;small intestine: 20.5,rectum: 6.4,Cell line enhanced,,ASC TERT1: 1.0;CAPAN-2: 1.8
89,MARVELD3,MRVLDC3,ENSG00000140832,MARVEL domain containing 3,16,71626161-71642114,"Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA043514, HPA045471",,,Approved,Vesicles<br>Intermediate filaments,Renal cancer:6.80e-10 (favourable),Mixed,Tissue enhanced,,small intestine: 37.1,duodenum: 31.5,Cell line enhanced,,BEWO: 29.9;CAPAN-2: 19.9;MCF7: 31.1;T-47d: 24.8
90,MGAM,MGA,ENSG00000257335,Maltase-glucoamylase,7,141907813-142106747,"Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins",Evidence at protein level,HPA002270,Enhanced,,,,Renal cancer:6.16e-5 (favourable),Tissue enriched,Tissue enhanced,,duodenum: 59.4;small intestine: 97.2,epididymis: 31.1,Cell line enhanced,,A549: 1.6;BJ hTERT+: 1.3;HL-60: 2.2;U-937: 3.4
91,MINOS1-NBL1,,ENSG00000270136,MINOS1-NBL1 readthrough,1,19596979-19658056,Predicted secreted proteins,Evidence at transcript level,HPA007394,Uncertain,,,,,Not detected,Tissue enhanced,,duodenum: 16.2;small intestine: 17.2,adipose tissue: 13.7,Cell line enhanced,,A-431: 25.2;BJ: 49.3;EFO-21: 25.9;HDLM-2: 32.5
92,MME,"CALLA, CD10, NEP",ENSG00000196549,Membrane metalloendopeptidase,3,155024124-155183729,"Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB000013, HPA052583, HPA056072",Enhanced,,,,,Mixed,Tissue enhanced,,duodenum: 428.2;kidney: 384.2;small intestine: 401.5,prostate: 162.5,Cell line enhanced,,ASC TERT1: 595.9;BJ hTERT+: 1084.7;HSkMC: 604.7
93,MNX1,"HB9, HLXB9, HOXHB9, SCRA1",ENSG00000130675,Motor neuron and pancreas homeobox 1,7,156994051-157010651,"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA071717,,,Approved,Nucleus<br>Nucleoli<br>Cytosol,,Mixed,Tissue enhanced,,duodenum: 7.3;small intestine: 6.7,colon: 3.7,Cell line enhanced,,AN3-CA: 16.0;EFO-21: 15.3;RPMI-8226: 25.9;SCLC-21H: 22.6
94,MS4A8,"CD20L5, MS4A4, MS4A8B",ENSG00000166959,Membrane spanning 4-domains A8,11,60699574-60715811,Predicted membrane proteins,Evidence at protein level,"HPA007318, HPA007319",Enhanced,,,,,Tissue enhanced,Tissue enhanced,,duodenum: 186.5;fallopian tube: 226.5;small intestine: 210.9,stomach: 49.1,Cell line enhanced,,SCLC-21H: 1.1
95,MT1H,MT1,ENSG00000205358,Metallothionein 1H,16,56669814-56671129,Predicted intracellular proteins,Evidence at protein level,,,,,,"Glioma:4.29e-7 (unfavourable), Renal cancer:5.44e-5 (unfavourable)",Tissue enhanced,Tissue enhanced,,kidney: 501.3;small intestine: 335.4;thyroid gland: 541.2,liver: 136.0,Cell line enhanced,,BEWO: 1.1;EFO-21: 3.4;SCLC-21H: 1.0
96,MUC3A,MUC3,ENSG00000169894,"Mucin 3A, cell surface associated",7,100949555-100968346,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA010871,Uncertain,,,,,Tissue enhanced,Tissue enhanced,,duodenum: 41.6;gallbladder: 21.8;small intestine: 37.1,rectum: 13.1,Cell line enhanced,,CACO-2: 6.0;CAPAN-2: 2.1;U-2 OS: 1.4
97,MYO7B,,ENSG00000169994,Myosin VIIB,2,127535802-127637729,Predicted intracellular proteins,Evidence at protein level,HPA039131,Enhanced,,,,Renal cancer:1.25e-4 (favourable),Group enriched,Tissue enhanced,,duodenum: 113.9;small intestine: 92.1,colon: 35.2,Cell line enriched,17.0,MOLT-4: 228.8
98,NAGS,"AGAS, ARGA, NAT7",ENSG00000161653,N-acetylglutamate synthase,17,44004546-44009063,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA027300,,,Supported,Mitochondria,,Expressed in all,Tissue enhanced,,duodenum: 14.8;small intestine: 13.6,liver: 5.0,Cell line enhanced,,HHSteC: 4.0;TIME: 5.0;U-87 MG: 8.7
99,NAPRT,"NAPRT1, PP3856",ENSG00000147813,Nicotinate phosphoribosyltransferase,8,143574785-143578649,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA023739, HPA024017, CAB068206, CAB068207",Enhanced,,Approved,Nucleus<br>Golgi apparatus<br>Cytosol,Renal cancer:6.28e-4 (favourable),Expressed in all,Tissue enhanced,,duodenum: 21.4;small intestine: 20.7,bone marrow: 9.6,Cell line enhanced,,CAPAN-2: 33.3;SK-BR-3: 30.1
100,NEUROD1,"BETA2, BHF-1, bHLHa3, MODY6, NEUROD",ENSG00000162992,Neuronal differentiation 1,2,181673088-181680876,"Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA003278, CAB022450",Approved,,,,Glioma:6.83e-5 (favourable),Tissue enhanced,Tissue enhanced,,cerebral cortex: 5.9;duodenum: 6.0;small intestine: 4.4;stomach: 4.9,pancreas: 1.8,Cell line enriched,79.0,SCLC-21H: 331.4
101,NEUROG3,"Atoh5, bHLHa7, Math4B, ngn3",ENSG00000122859,Neurogenin 3,10,69571698-69573238,"Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA039785,Uncertain,,,,,Tissue enhanced,Tissue enhanced,,duodenum: 2.8;small intestine: 1.3,"colon,rectum: 0.4",Group enriched,19.0,HMC-1: 1.7;THP-1: 7.1
102,NKX2-3,"CSX3, NKX2.3, NKX2C, NKX4-3",ENSG00000119919,NK2 homeobox 3,10,99532933-99536524,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA047561,Uncertain,,Uncertain,Nucleoli<br>Cytosol,,Tissue enhanced,Tissue enhanced,,small intestine: 12.7;spleen: 29.6,duodenum: 11.5,Cell line enhanced,,NB-4: 1.1;REH: 2.0
103,NPC1L1,,ENSG00000015520,NPC1 like intracellular cholesterol transporter 1,7,44512535-44541315,"FDA approved drug targets, Predicted membrane proteins",Evidence at protein level,"CAB070127, CAB070128",Enhanced,,,,,Group enriched,Tissue enhanced,,duodenum: 57.1;small intestine: 57.9,liver: 14.2,Group enriched,7.0,CACO-2: 5.9;Hep G2: 12.2;SCLC-21H: 17.4
104,NR1H4,"FXR, HRR-1, HRR1, RIP14",ENSG00000012504,Nuclear receptor subfamily 1 group H member 4,12,100473708-100564413,"Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors, Transporters",Evidence at protein level,HPA047699,,,Approved,Nucleoplasm,,Group enriched,Tissue enhanced,,liver: 66.6;small intestine: 44.4,kidney: 29.9,Group enriched,26.0,Hep G2: 20.2;HHSteC: 14.1;RPTEC TERT1: 34.8
105,OLFM4,"GC1, GW112, OlfD",ENSG00000102837,Olfactomedin 4,13,53028759-53052057,Predicted secreted proteins,Evidence at protein level,HPA077718,Enhanced,,,,Breast cancer:8.77e-4 (favourable),Group enriched,Tissue enhanced,,duodenum: 1193.9;rectum: 611.5;small intestine: 1437.8,colon: 445.0,Cell line enhanced,,BEWO: 5.1;BJ hTERT+: 15.0;HaCaT: 22.9
106,OMP,,ENSG00000254550,Olfactory marker protein,11,77102840-77103331,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Mixed,Tissue enhanced,,duodenum: 2.7;small intestine: 2.8,rectum: 2.0,Not detected,,
107,OXT,"OT, OT-NPI, OXT-NPI",ENSG00000101405,Oxytocin/neurophysin I prepropeptide,20,3071620-3072517,"Plasma proteins, Predicted secreted proteins",Evidence at protein level,HPA071892,Supported,Supported,,,,Tissue enriched,Tissue enhanced,,liver: 2.1;small intestine: 1.1,duodenum: 1.1,Cell line enhanced,,CACO-2: 1.3;HMC-1: 1.0
108,PDZD3,"FLJ22756, IKEPP, PDZK2",ENSG00000172367,PDZ domain containing 3,11,119185457-119190223,Predicted intracellular proteins,Evidence at protein level,,,,,,,Tissue enhanced,Tissue enhanced,,duodenum: 17.3;kidney: 10.8;small intestine: 21.2,rectum: 6.7,Not detected,,
109,PDZD7,"bA108L7.8, DFNB57, FLJ23209, PDZK7",ENSG00000186862,PDZ domain containing 7,10,101007683-101031157,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,,,,,,,Not detected,Tissue enhanced,,small intestine: 13.2,cerebral cortex: 8.9,Cell line enhanced,,SCLC-21H: 16.1;THP-1: 10.8
110,PDZK1,"NHERF3, PDZD1",ENSG00000174827,PDZ domain containing 1,1,145670852-145708148,Predicted intracellular proteins,Evidence at protein level,"HPA005755, HPA006155, CAB008971",Enhanced,,Approved,Nucleoplasm<br>Vesicles<br>Cytosol,Renal cancer:2.54e-7 (favourable),Group enriched,Tissue enhanced,,kidney: 561.5;small intestine: 127.1,duodenum: 69.0,Cell line enhanced,,CACO-2: 83.6;RPTEC TERT1: 168.6;T-47d: 547.9
111,PLA2G2A,"PLA2B, PLA2L",ENSG00000188257,Phospholipase A2 group IIA,1,19975431-19980416,"Enzymes, FDA approved drug targets, Predicted secreted proteins, RAS pathway related proteins",Evidence at protein level,HPA015236,Enhanced,,Uncertain,Nucleus<br>Nucleoli,Melanoma:1.49e-4 (favourable),Expressed in all,Tissue enhanced,,colon: 108.4;rectum: 177.5;small intestine: 233.7,duodenum: 85.7,Group enriched,11.0,Hep G2: 50.2;RT4: 53.3
112,PLEKHG6,"FLJ10665, MYOGEF",ENSG00000008323,Pleckstrin homology and RhoGEF domain containing G6,12,6310436-6328506,Predicted intracellular proteins,Evidence at protein level,"HPA041459, HPA058230",Uncertain,,Supported,Cell Junctions<br>Centrosome,,Mixed,Tissue enhanced,,small intestine: 47.7,duodenum: 36.5,Cell line enhanced,,BEWO: 147.7;CACO-2: 41.4;RT4: 42.4
113,PLS1,"I-plastin, Plastin-1",ENSG00000120756,Plastin 1,3,142596387-142713664,Predicted intracellular proteins,Evidence at protein level,HPA055744,Enhanced,,,,"Renal cancer:8.76e-6 (favourable), Pancreatic cancer:4.84e-4 (unfavourable)",Mixed,Tissue enhanced,,duodenum: 192.4;small intestine: 348.5,rectum: 152.0,Cell line enhanced,,BEWO: 108.3;RPTEC TERT1: 108.5
114,PRELID2,"FLJ38376, MGC21644",ENSG00000186314,PRELI domain containing 2,5,145471799-145835369,Predicted intracellular proteins,Evidence at transcript level,HPA042486,Uncertain,,Approved,Nucleoplasm,"Renal cancer:9.65e-6 (unfavourable), Pancreatic cancer:3.78e-4 (unfavourable)",Mixed,Tissue enhanced,,small intestine: 28.7,rectum: 19.2,Mixed,,
115,PRKG2,"cGKII, PRKGR2",ENSG00000138669,"Protein kinase, cGMP-dependent, type II",4,81087370-81215117,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA007386, CAB018739",Approved,,,,,Tissue enhanced,Tissue enhanced,,prostate: 15.3;small intestine: 14.4,duodenum: 9.7,Cell line enhanced,,HEL: 18.8;SCLC-21H: 7.3
116,PRODH,"HSPOX2, PIG6, PRODH1, PRODH2, TP53I6",ENSG00000100033,Proline dehydrogenase 1,22,18912777-18936553,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA020361,Uncertain,,,,Cervical cancer:1.54e-4 (favourable),Tissue enhanced,Tissue enhanced,,small intestine: 25.2,duodenum: 5.7,Cell line enriched,6.0,RPTEC TERT1: 28.5
117,PRORY,CYorf17,ENSG00000183146,"Proline rich, Y-linked",Y,21382954-21386360,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Not detected,Tissue enhanced,,small intestine: 1.8,"colon,rectum: 0.6",Cell line enhanced,,U-266/84: 2.4
118,PTGDR2,"CD294, CRTH2, DP2, GPR44",ENSG00000183134,Prostaglandin D2 receptor 2,11,60850940-60855971,"CD markers, G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,HPA014259,Uncertain,,,,,Mixed,Tissue enhanced,,small intestine: 7.1;stomach: 7.5,parathyroid gland: 5.0,Cell line enhanced,,HEL: 8.5;Hep G2: 3.2;HMC-1: 5.1;K-562: 3.6;NB-4: 8.7
119,PTPRH,SAP-1,ENSG00000080031,"Protein tyrosine phosphatase, receptor type H",19,55181248-55209506,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA042300,,,Approved,Mitochondria,,Mixed,Tissue enhanced,,duodenum: 68.9;small intestine: 77.0,gallbladder: 38.6,Cell line enhanced,,HHSteC: 10.1;K-562: 13.5;SK-MEL-30: 17.2
120,R3HDML,dJ881L22.3,ENSG00000101074,R3H domain containing like,20,44336986-44351235,Predicted secreted proteins,Evidence at protein level,HPA070264,Enhanced,,,,,Tissue enhanced,Tissue enhanced,,duodenum: 2.2;small intestine: 2.7,testis: 0.8,Not detected,,
121,RBBP8NL,"C20orf151, dJ908M14.3",ENSG00000130701,RBBP8 N-terminal like,20,62410237-62427533,Predicted intracellular proteins,Evidence at protein level,HPA042627,Uncertain,,,,Urothelial cancer:6.91e-4 (favourable),Mixed,Tissue enhanced,,small intestine: 5.2,duodenum: 4.5,Cell line enhanced,,BEWO: 17.9;CACO-2: 22.7;MCF7: 8.7;SK-BR-3: 9.3
122,REG1B,"PSPS2, REGH, REGI-BETA, REGL",ENSG00000172023,Regenerating family member 1 beta,2,79085030-79088019,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA045549, HPA045579",Supported,,,,,Tissue enhanced,Tissue enhanced,,duodenum: 734.2;small intestine: 435.2,pancreas: 181.6,Cell line enhanced,,EFO-21: 6.0;HDLM-2: 3.9;U-2 OS: 15.6;U-251 MG: 3.2
123,RNF186,FLJ20225,ENSG00000178828,Ring finger protein 186,1,19814029-19815278,Predicted membrane proteins,Evidence at protein level,"HPA034547, HPA035558",Enhanced,,,,,Tissue enhanced,Tissue enhanced,,duodenum: 132.4;epididymis: 82.2;small intestine: 46.5,kidney: 26.2,Cell line enhanced,,RPMI-8226: 1.2
124,RP11-20I23.3,,ENSG00000259784,,16,2513965-2527955,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Not detected,Tissue enhanced,,bone marrow: 1.1;small intestine: 1.3,smooth muscle: 0.5,Cell line enhanced,,REH: 1.4
125,RP11-407N17.3,,ENSG00000258941,CTAGE family member 5 isoform 8 precursor ,14,39233902-39350423,Predicted membrane proteins,Evidence at protein level,"HPA000387, HPA000922, HPA054066, HPA055459",Uncertain,,Approved,Endoplasmic reticulum,,Not detected,Tissue enhanced,,duodenum: 23.9;liver: 22.8;parathyroid gland: 44.1;small intestine: 29.5,kidney: 19.0,Cell line enhanced,,CAPAN-2: 17.3;EFO-21: 5.5;Hep G2: 8.5;RPTEC TERT1: 7.0
126,SDCBP2,"SITAC18, ST-2",ENSG00000125775,Syndecan binding protein 2,20,1309909-1329239,Predicted intracellular proteins,Evidence at protein level,"HPA054554, HPA064490",Enhanced,,Approved,Vesicles<br>Cytosol,"Lung cancer:2.42e-4 (unfavourable), Pancreatic cancer:3.07e-4 (unfavourable), Urothelial cancer:3.37e-4 (favourable)",Expressed in all,Tissue enhanced,,duodenum: 135.1;small intestine: 143.9,stomach: 94.5,Cell line enhanced,,CAPAN-2: 16.0
127,SEC16B,"LZTR2, PGPR-p117, RGPR, Sec16S",ENSG00000120341,"SEC16 homolog B, endoplasmic reticulum export factor",1,177923956-177984303,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA054292, HPA072913",Enhanced,,Approved,Endoplasmic reticulum<br>Plasma membrane<br>Actin filaments,,Not detected,Tissue enhanced,,duodenum: 28.2;small intestine: 30.9,liver: 18.8,Cell line enhanced,,CAPAN-2: 6.3;EFO-21: 5.1;HDLM-2: 5.3
128,SECTM1,K12,ENSG00000141574,Secreted and transmembrane 1,17,82321024-82334074,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA051214,Approved,,,,,Expressed in all,Tissue enhanced,,small intestine: 96.6,duodenum: 64.4,Cell line enhanced,,SiHa: 125.5;U-2197: 82.3
129,SFRP5,SARP3,ENSG00000120057,Secreted frizzled related protein 5,10,97766751-97771952,Predicted secreted proteins,Evidence at protein level,,,,,,,Tissue enhanced,Tissue enhanced,,duodenum: 30.9;pancreas: 31.2;small intestine: 29.4,adrenal gland: 12.9,Cell line enhanced,,A549: 2.3;CACO-2: 10.5;RPMI-8226: 3.2;SCLC-21H: 2.4
130,SH3D21,"C1orf113, FLJ22938",ENSG00000214193,SH3 domain containing 21,1,36306387-36324886,Predicted intracellular proteins,Evidence at protein level,"HPA042212, HPA042456, HPA066168",Approved,,Approved,Nucleus<br>Plasma membrane,"Renal cancer:1.76e-6 (unfavourable), Breast cancer:2.60e-4 (favourable)",Mixed,Tissue enhanced,,small intestine: 22.2,skin: 15.5,Cell line enhanced,,HaCaT: 15.2
131,SLC13A2,NaDC-1,ENSG00000007216,Solute carrier family 13 member 2,17,28473293-28497781,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA014963,Enhanced,,,,Renal cancer:9.00e-4 (favourable),Mixed,Tissue enhanced,,duodenum: 68.7;small intestine: 54.3,kidney: 19.7,Not detected,,
132,SLC17A8,"DFNA25, VGLUT3",ENSG00000179520,Solute carrier family 17 member 8,12,100357079-100422059,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,CAB079058,,Supported,,,,Tissue enhanced,Tissue enhanced,,small intestine: 5.8,cerebral cortex: 1.2,Not detected,,
133,SLC1A1,"EAAC1, EAAT3",ENSG00000106688,Solute carrier family 1 member 1,9,4490444-4587469,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,"CAB015466, HPA020086",Approved,,,,Renal cancer:2.86e-8 (favourable),Expressed in all,Tissue enhanced,,small intestine: 71.2,epididymis: 54.5,Cell line enhanced,,HDLM-2: 65.4;RPTEC TERT1: 50.1
134,SLC22A18,"BWR1A, BWSCR1A, IMPT1, ITM, ORCTL2, SLC22A1L, TSSC5",ENSG00000110628,Solute carrier family 22 member 18,11,2899721-2925246,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA067812, HPA071461",Enhanced,,,,,Expressed in all,Tissue enhanced,,duodenum: 43.2;small intestine: 31.7,colon: 10.3,Cell line enhanced,,CAPAN-2: 28.3;Karpas-707: 21.3
135,SLC23A3,"FLJ31168, SVCT3, Yspl1",ENSG00000213901,Solute carrier family 23 member 3,2,219161465-219170095,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA019059,,,Approved,Nucleus<br>Cell Junctions,,Tissue enriched,Tissue enhanced,,kidney: 53.1;small intestine: 22.9,duodenum: 8.7,Cell line enhanced,,hTCEpi: 3.5
136,SLC25A34,DKFZp781A10161,ENSG00000162461,Solute carrier family 25 member 34,1,15736405-15741396,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA069806,,,Supported,Mitochondria,,Mixed,Tissue enhanced,,duodenum: 14.5;small intestine: 15.2,skeletal muscle: 8.2,Mixed,,
137,SLC28A2,"CNT2, HCNT2, HsT17153, SPNT1",ENSG00000137860,Solute carrier family 28 member 2,15,45252230-45277845,"Predicted membrane proteins, Transporters",Evidence at protein level,"HPA046068, HPA055623",Enhanced,,,,,Tissue enhanced,Tissue enhanced,,duodenum: 64.9;rectum: 37.1;small intestine: 97.9,stomach: 21.0,Not detected,,
138,SLC2A5,GLUT5,ENSG00000142583,Solute carrier family 2 member 5,1,9035107-9088478,"Plasma proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA005449,Enhanced,,,,Renal cancer:5.44e-5 (unfavourable),Group enriched,Tissue enhanced,,duodenum: 109.0;small intestine: 92.6;testis: 139.9,bone marrow: 64.4,Cell line enhanced,,Daudi: 134.4;U-266/70: 111.0;U-698: 121.2;U-937: 52.9
139,SLC51A,OSTalpha,ENSG00000163959,Solute carrier family 51 alpha subunit,3,196211487-196243178,"Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters",Evidence at protein level,HPA039123,Enhanced,,,,Liver cancer:7.54e-4 (favourable),Tissue enriched,Tissue enhanced,,duodenum: 29.3;liver: 35.1;small intestine: 71.3,colon: 9.9,Cell line enhanced,,REH: 3.4
140,SLC51B,OSTbeta,ENSG00000186198,Solute carrier family 51 beta subunit,15,65045370-65053396,"Predicted membrane proteins, Transporters",Evidence at protein level,"HPA008398, HPA008533",Enhanced,,Approved,Vesicles<br>Mitochondria,Renal cancer:8.46e-5 (favourable),Tissue enhanced,Tissue enhanced,,"cervix, uterine: 59.7;duodenum: 85.4;small intestine: 118.4",colon: 40.7,Group enriched,9.0,CACO-2: 15.0;EFO-21: 11.0;Hep G2: 10.4
141,SLC6A20,"XT3, Xtrp3",ENSG00000163817,Solute carrier family 6 member 20,3,45755450-45796535,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,HPA029873,Uncertain,,,,Renal cancer:1.55e-5 (favourable),Mixed,Tissue enhanced,,duodenum: 24.4;small intestine: 19.3,gallbladder: 10.9,Cell line enhanced,,HaCaT: 1.5
142,SLC9A3,NHE3,ENSG00000066230,Solute carrier family 9 member A3,5,473310-524332,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA036493, HPA036669",Enhanced,,Supported,Plasma membrane,Melanoma:8.49e-4 (unfavourable),Mixed,Tissue enhanced,,colon: 80.9;gallbladder: 66.1;small intestine: 72.6,kidney: 57.3,Cell line enhanced,,HDLM-2: 30.4
143,SMPD3,NSMASE2,ENSG00000103056,Sphingomyelin phosphodiesterase 3,16,68358325-68448688,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB033885, HPA065535, HPA069383",Approved,,Supported,Endoplasmic reticulum,"Endometrial cancer:3.86e-4 (favourable), Cervical cancer:7.72e-4 (favourable)",Mixed,Tissue enhanced,,duodenum: 61.0;small intestine: 62.9,stomach: 22.6,Cell line enhanced,,HMC-1: 8.5;MOLT-4: 11.7;RPMI-8226: 8.3;SCLC-21H: 15.6
144,SOWAHA,ANKRD43,ENSG00000198944,Sosondowah ankyrin repeat domain family member A,5,132813587-132816797,Predicted secreted proteins,Evidence at protein level,HPA064621,Approved,,,,"Renal cancer:9.38e-5 (favourable), Pancreatic cancer:4.03e-4 (favourable)",Mixed,Tissue enhanced,,duodenum: 39.7;small intestine: 46.6,cerebral cortex: 22.1,Group enriched,8.0,SCLC-21H: 17.0;T-47d: 32.7
145,SSUH2,"C3orf32, fls485, ssu-2",ENSG00000125046,Ssu-2 homolog (C. elegans),3,8619400-8745040,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA049777,Approved,,,,,Mixed,Tissue enhanced,,duodenum: 4.2;small intestine: 3.9;testis: 4.0,spleen: 1.5,Cell line enriched,13.0,Hep G2: 18.2
146,SULT1A2,"HAST4, STP2",ENSG00000197165,Sulfotransferase family 1A member 2,16,28591943-28597109,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA049500, HPA051051",Supported,,,,,Tissue enhanced,Tissue enhanced,,duodenum: 49.2;small intestine: 49.2,liver: 21.0,Cell line enhanced,,BEWO: 9.6;EFO-21: 12.0;Hep G2: 33.5
147,SULT1A4,,ENSG00000213648,Sulfotransferase family 1A member 4,16,29459889-29464976,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA049500, HPA051051",Supported,,,,,Not detected,Tissue enhanced,,duodenum: 173.4;small intestine: 131.0,colon: 38.4,Cell line enhanced,,CAPAN-2: 107.9;EFO-21: 93.9;HEL: 76.5;Hep G2: 188.0;Karpas-707: 114.2
148,TBC1D3,"DKFZp434P2235, PRC17, TBC1D3A",ENSG00000274611,TBC1 domain family member 3,17,38181659-38192541,Predicted membrane proteins,Evidence at protein level,"HPA046969, HPA047745, HPA052553",Approved,,Uncertain,Vesicles,,Not detected,Tissue enhanced,,small intestine: 4.0;testis: 6.8,endometrium: 3.6,Cell line enhanced,,AF22: 7.5;REH: 4.5;U-138 MG: 6.4;U-266/70: 7.8;U-266/84: 3.0;U-698: 3.6
149,TBC1D3D,,ENSG00000274419,TBC1 domain family member 3D,17,38003976-38014902,Predicted membrane proteins,Evidence at protein level,"HPA046969, HPA047745, HPA052553",Approved,,Uncertain,Vesicles,,Not detected,Tissue enhanced,,small intestine: 5.5;testis: 3.4,skin: 3.2,Cell line enhanced,,CAPAN-2: 8.4;HaCaT: 6.1;HeLa: 5.2;RT4: 3.7
150,TEN1-CDK3,,ENSG00000261408,TEN1-CDK3 readthrough (NMD candidate),17,75979231-76005999,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Mixed,Tissue enhanced,,small intestine: 1.4,"adipose tissue,spleen: 1.1",Cell line enhanced,,BEWO: 2.6;SH-SY5Y: 3.9
151,TGFBR3L,,ENSG00000260001,Transforming growth factor beta receptor 3 like,19,7916145-7919097,Predicted membrane proteins,Evidence at protein level,HPA074356,Supported,,Approved,Vesicles,,Mixed,Tissue enhanced,,duodenum: 1.7;small intestine: 1.8,kidney: 1.0,Cell line enhanced,,PC-3: 3.7;REH: 9.0
152,TJP3,ZO-3,ENSG00000105289,Tight junction protein 3,19,3708109-3750813,Predicted intracellular proteins,Evidence at protein level,"CAB013244, HPA046863, HPA053337",Enhanced,,Enhanced,Nucleoplasm<br>Cell Junctions,"Renal cancer:9.36e-8 (favourable), Endometrial cancer:1.83e-6 (favourable), Head and neck cancer:9.52e-4 (favourable)",Mixed,Tissue enhanced,,duodenum: 41.5;small intestine: 41.3,colon: 30.6,Cell line enhanced,,BEWO: 42.4;CAPAN-2: 39.5;SK-BR-3: 19.4;T-47d: 51.5
153,TLDC2,"C20orf118, dJ132F21.2",ENSG00000101342,TBC/LysM-associated domain containing 2,20,36876121-36894235,Predicted intracellular proteins,Evidence at transcript level,HPA047468,Approved,,,,Renal cancer:9.97e-5 (unfavourable),Tissue enhanced,Tissue enhanced,,duodenum: 19.0;small intestine: 20.1,rectum: 13.3,Cell line enriched,10.0,HMC-1: 30.5
154,TMC5,FLJ13593,ENSG00000103534,Transmembrane channel like 5,16,19410496-19499113,Predicted membrane proteins,Evidence at protein level,"HPA040810, HPA042037",Enhanced,,Approved,Nucleus<br>Plasma membrane,Liver cancer:7.96e-4 (unfavourable),Mixed,Tissue enhanced,,small intestine: 59.1,duodenum: 45.4,Cell line enriched,6.0,CAPAN-2: 61.8
155,TMEM150B,"TMEM224, TTN2",ENSG00000180061,Transmembrane protein 150B,19,55312801-55334048,Predicted membrane proteins,Evidence at transcript level,,,,,,Renal cancer:6.14e-6 (unfavourable),Tissue enhanced,Tissue enhanced,,duodenum: 69.8;small intestine: 66.5,lung: 18.9,Cell line enhanced,,CACO-2: 7.6;HMC-1: 4.0;U-937: 16.3
156,TMEM238,,ENSG00000233493,Transmembrane protein 238,19,55379245-55384598,Predicted membrane proteins,Evidence at protein level,,,,,,Renal cancer:8.84e-6 (favourable),Expressed in all,Tissue enhanced,,small intestine: 10.0;stomach: 9.9,colon: 9.1,Cell line enhanced,,A-431: 17.0;HaCaT: 15.4
157,TMEM252,"C9orf71, MGC34760",ENSG00000181778,Transmembrane protein 252,9,68536580-68540867,Predicted membrane proteins,Evidence at transcript level,,,,,,Renal cancer:1.75e-7 (favourable),Tissue enriched,Tissue enhanced,,kidney: 37.5;small intestine: 25.7,esophagus: 6.8,Cell line enhanced,,PC-3: 1.1;RPTEC TERT1: 1.8;SK-BR-3: 1.0
158,TMEM45B,"BC016153, FLJ40787",ENSG00000151715,Transmembrane protein 45B,11,129815819-129860003,Predicted membrane proteins,Evidence at protein level,HPA015878,Approved,,Uncertain,Nucleoplasm<br>Cytosol,,Expressed in all,Tissue enhanced,,duodenum: 136.2;small intestine: 139.1,rectum: 103.3,Cell line enhanced,,CACO-2: 32.2;Hep G2: 27.4;PC-3: 45.6;RT4: 105.7;T-47d: 34.7
159,TMEM82,,ENSG00000162460,Transmembrane protein 82,1,15742422-15747982,Predicted membrane proteins,Evidence at protein level,HPA060282,Uncertain,,Uncertain,Nucleoplasm<br>Cytosol,Renal cancer:3.80e-7 (favourable),Tissue enhanced,Tissue enhanced,,duodenum: 23.0;liver: 9.0;small intestine: 19.4,kidney: 7.6,Cell line enriched,5.0,CACO-2: 2.6
160,TMEM92,FLJ33318,ENSG00000167105,Transmembrane protein 92,17,50271406-50281485,Predicted membrane proteins,Evidence at protein level,"HPA063009, HPA069820",Approved,,Supported,Nucleoplasm,"Renal cancer:1.14e-6 (unfavourable), Head and neck cancer:8.35e-4 (unfavourable)",Mixed,Tissue enhanced,,duodenum: 40.2;small intestine: 50.6,gallbladder: 21.8,Cell line enhanced,,A549: 16.5;CACO-2: 25.7;CAPAN-2: 25.7;EFO-21: 56.2
161,TPSG1,"PRSS31, TMT",ENSG00000116176,Tryptase gamma 1,16,1221651-1225257,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA060458,Enhanced,,,,Renal cancer:1.76e-8 (unfavourable),Tissue enhanced,Tissue enhanced,,colon: 14.6;duodenum: 14.3;rectum: 9.5;small intestine: 10.5,ovary: 2.5,Group enriched,8.0,HMC-1: 20.4;MCF7: 6.0
162,TREH,"MGC129621, TRE, TREA",ENSG00000118094,Trehalase,11,118657316-118679690,"Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins",Evidence at protein level,"HPA039913, HPA042045",Enhanced,,,,"Renal cancer:2.33e-6 (favourable), Liver cancer:3.76e-4 (favourable)",Mixed,Tissue enhanced,,duodenum: 60.6;small intestine: 72.6,kidney: 13.5,Cell line enhanced,,BEWO: 1.5
163,TRPV3,VRL3,ENSG00000167723,Transient receptor potential cation channel subfamily V member 3,17,3510502-3557995,"Disease related genes, FDA approved drug targets, Predicted membrane proteins",Evidence at protein level,HPA069550,,,Approved,Plasma membrane<br>Centrosome<br>Cytosol,,Mixed,Tissue enhanced,,skin: 5.1;small intestine: 4.5,duodenum: 1.7,Cell line enhanced,,BEWO: 3.6;RH-30: 9.0;T-47d: 3.7
164,TSPAN8,"CO-029, TM4SF3",ENSG00000127324,Tetraspanin 8,12,71125085-71441898,"Cancer-related genes, Predicted membrane proteins",Evidence at protein level,"CAB026009, HPA044337",Enhanced,,Approved,Nucleoplasm,"Urothelial cancer:7.36e-5 (favourable), Renal cancer:9.66e-5 (unfavourable)",Tissue enhanced,Tissue enhanced,,colon: 910.6;duodenum: 905.9;rectum: 911.5;small intestine: 909.2,stomach: 573.4,Cell line enhanced,,CACO-2: 36.0;HeLa: 34.8;PC-3: 151.7;RT4: 30.6
165,TUBAL3,FLJ21665,ENSG00000178462,Tubulin alpha like 3,10,5393098-5404830,Predicted intracellular proteins,Evidence at protein level,"HPA045900, HPA063394",Uncertain,,,,,Tissue enhanced,Tissue enhanced,,duodenum: 24.4;small intestine: 31.0,colon: 11.8,Group enriched,6.0,HEL: 11.9;K-562: 3.8
166,UCN3,"SPC, UCNIII",ENSG00000178473,Urocortin 3,10,5365009-5374692,Predicted secreted proteins,Evidence at protein level,HPA038281,Uncertain,,,,,Group enriched,Tissue enhanced,,duodenum: 9.3;small intestine: 7.5,stomach: 3.6,Cell line enriched,10.0,SCLC-21H: 1.5
167,UGT1A10,UGT1J,ENSG00000242515,UDP glucuronosyltransferase family 1 member A10,2,233636454-233773305,"Cancer-related genes, Enzymes, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,,,,,,Pancreatic cancer:4.55e-4 (unfavourable),Tissue enhanced,Tissue enhanced,,colon: 49.7;duodenum: 80.9;small intestine: 59.1,rectum: 39.6,Cell line enriched,108.0,RT4: 416.9
168,UGT2A3,FLJ21934,ENSG00000135220,UDP glucuronosyltransferase family 2 member A3,4,68928463-68951791,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA045108,Supported,,,,"Renal cancer:6.07e-7 (favourable), Colorectal cancer:3.31e-4 (favourable)",Tissue enriched,Tissue enhanced,,duodenum: 82.1;gallbladder: 46.3;kidney: 46.8;small intestine: 85.9,rectum: 23.9,Cell line enriched,8.0,Hep G2: 13.5
169,UGT2B17,,ENSG00000197888,UDP glucuronosyltransferase family 2 member B17,4,68537184-68568527,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA045108,Supported,,,,,Group enriched,Tissue enhanced,,colon: 372.4;duodenum: 371.2;small intestine: 522.5,rectum: 151.7,Cell line enhanced,,RPMI-8226: 1.2
170,UNC5CL,"MGC34763, ZUD",ENSG00000124602,Unc-5 family C-terminal like,6,41026911-41039217,Predicted intracellular proteins,Evidence at protein level,HPA015725,Enhanced,,Approved,Centrosome,,Mixed,Tissue enhanced,,duodenum: 37.3;small intestine: 32.4;stomach: 23.8,kidney: 15.0,Cell line enhanced,,CACO-2: 5.8;RPTEC TERT1: 10.0
171,USH1C,"AIE-75, DFNB18, harmonin, NY-CO-37, NY-CO-38, PDZ-73, PDZ73, PDZD7C",ENSG00000006611,USH1 protein network component harmonin,11,17493895-17544416,"Cancer-related genes, Disease related genes, Predicted intracellular proteins",Evidence at protein level,"CAB013690, HPA027398, HPA027492, HPA028033",Supported,,Enhanced,Cytosol,"Liver cancer:2.20e-4 (unfavourable), Renal cancer:9.41e-4 (favourable)",Group enriched,Tissue enhanced,,duodenum: 99.2;small intestine: 106.9,kidney: 55.4,Cell line enhanced,,CACO-2: 50.5;CAPAN-2: 7.4;HeLa: 14.4
172,XDH,"XO, XOR",ENSG00000158125,Xanthine dehydrogenase,2,31334321-31414715,"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA062641, HPA069323",Supported,,Supported,Nucleus,Urothelial cancer:8.73e-6 (favourable),Mixed,Tissue enhanced,,breast: 48.3;duodenum: 45.6;liver: 35.9;small intestine: 54.6,colon: 11.2,Cell line enhanced,,HBEC3-KT: 14.4;hTERT-HME1: 23.9
173,ZNF511-PRAP1,,ENSG00000283496,ZNF511-PRAP1 readthrough,10,133309410-133352529,Predicted membrane proteins,Evidence at protein level,"HPA035360, HPA038713, HPA052451",Supported,,Uncertain,Nucleoplasm<br>Vesicles<br>Plasma membrane,,,Tissue enhanced,,duodenum: 25.2;small intestine: 25.0,kidney: 10.7,Cell line enhanced,,Hep G2: 11.3
